



Nyrada Board Changes

- Global pharmaceutical leader, Dr. Gisela Mautner appointed as Non-Executive Director
- Dr. Mautner brings over 20 years of extensive leadership experience across operational, medical, and scientific advisory roles covering multiple therapeutic areas
- Non-Executive Director, Peter Marks retires from the Board having supported Nyrada through its IPO and key first years as a listed company

Sydney, 2 August 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announces the appointment of Dr. Gisela Mautner as a Non-Executive Director to its Board. The Company also announces the retirement of Non-Executive Director, Peter Marks. Mr Marks has been a member of the Board since before the Company listed in January 2020 and retires from the Nyrada Board to pursue a range of other interests. Both Board changes are effective from 1 August 2022.

Nyrada Non-Executive Chairman, John Moore said: “On behalf of the Board, I would like to thank Peter for his valuable contribution to Nyrada during his term as Director, particularly as a member of the Audit and Risk Committee. Peter has been instrumental in supporting the early growth of the Company, leveraging his deep capital markets knowledge and networks to support our growth objectives. He assisted in the Company’s pre-IPO raising as well as guiding the Company through the IPO process and beyond.

“I am delighted Dr. Mautner has agreed to join our Board, bringing significant experience across clinical product development. As part of our regular planning processes and our commitment to ensuring a diverse mix of key skills, knowledge and experience, the Board identified the need for clinical development experience to guide the Company as it enters its next phase. Dr. Mautner’s experience overseeing drug development at some of the world’s leading pharmaceutical companies will be invaluable as Nyrada’s programs advance towards the clinic,” Mr. Moore added.

Dr. Mautner is a medical doctor with extensive pharmaceutical industry experience encompassing all aspects of drug development, from clinical research through to product commercialisation. She is a seasoned senior leader, having held positions at MSD (Merck), Bayer and Amgen, where she successfully launched several new drugs in different therapeutic areas, including in cardiovascular diseases.

Dr. Mautner initiated and led the foundational research at the National Institutes of Health (US) that linked electron-beam CT images as a reliable proxy to evaluate and quantify atherosclerotic plaques. Recent studies suggest PCSK9 may be an interesting therapeutic target for prevention of atherosclerosis beyond LDL-cholesterol regulation.¹

¹ Cheng et al 2016

Dr. Mautner is the Chief Executive Officer and Managing Director of Noxopharm (ASX: NOX), previously serving as its Chief Medical Officer since 2019 (Noxopharm has a significant holding in Nyrada). She holds a Doctor of Medicine and PhD from Germany, a Master of Public Health from Harvard University, and a Master of Business Administration from Northwestern University of Chicago.

Dr. Mautner will stand for election at Nyrada's AGM in November 2022.

- ENDS -

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery, and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:

Laura Vize, Investor Relations Manager
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.